Liver Cirrhosis Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 – 2028)

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Liver Cirrhosis Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 – 2028)

  • 207 Pages | Published On: 4-Feb-19 | Format:PDF | Last Updated: 4-Feb-19
  • GervanoRA’s Market Estimation report “Liver Cirrhosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)” analyzed the current and upcoming opportunities in the Liver Cirrhosis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Liver Cirrhosis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Liver Cirrhosis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Liver Cirrhosis Drug Class, Route of Administration and Distribution Channel. Report primarily focuses on the patent analysis of the key pipeline drugs to provide a brief understanding about the market opportunities in the Liver Cirrhosis competitive environment. We have also prognosticated the Liver Cirrhosis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Epidemiology and Epidemiology forecast 2018-2023
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Timelines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    2.1. MARKET SNAPSHOT, 2018-2028
    2.2. KEY PIPELINE EVENTS (REGULATORY APPROVALS) 2020-2035
    2.3. KEY MAJOR FINDINGS
    2.3.1. DRIVERS
    2.3.2. RESTRAINTS
    2.3.3. OPPORTUNITIES
    3 DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4 MARKET DYNAMICS
    4.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    5 PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PHASE 3 MOLECULES
    5.1.2. PHASE 2 MOLECULES
    5.1.3. PHASE 1 MOLECULES
    5.1.4. PRECLINICAL MOLECULES
    5.1.5. EARLY R&D MOLECULES
    5.2. PIPELINE ANALYSIS BY INDICATION
    5.3. PIPELINE ANALYSIS BY GEOGRAPHY
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY DRUG CLASS
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.6.1. UNMET NEEDS AND OPPORTUNITIES
    5.7. ESTIMATED APPROVAL TIMELINES
    5.7.1. METHODOLOGY
    5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    6 LIVER CIRRHOSIS CLINICAL TRIALS SUMMARY
    6.1. LIVER CIRRHOSIS PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    6.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
    6.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
    6.2. ONGOING CLINICAL TRIALS SUMMARY
    7 GLOBAL LIVER DISEASES MARKET BY DRUG CLASS
    7.1. DIURETICS
    7.2. ANTIVIRAL DRUGS
    7.3. BETA-BLOCKERS (Β-BLOCKERS)
    7.4. HORMONES
    7.5. ANTIBIOTICS
    7.6. AMMONIA REDUCER
    8 LIVER CIRRHOSIS MARKET, BY ROUTE OF ADMINISTRATION
    8.1. ORAL
    8.2. INJECTABLES
    9 LIVER CIRRHOSIS MARKET, BY DISTRIBUTION CHANNEL
    9.1. HOSPITAL PHARMACIES
    9.2. RETAIL PHARMACIES
    9.3. ONLINE PHARMACIES
    10 GLOBAL LIVER CIRRHOSIS THERAPEUTIC MARKET BY GEOGRAPHY
    9.1 US
    9.2 UK
    9.3 GERMANY
    9.4 FRANCE
    9.5 ITALY
    9.6 SPAIN
    9.7 JAPAN
    9.8 CHINA
    9.9 INDIA
    9.1 BRAZIL
    9.11 RUSSIA
    9.12 ROW
    11 CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    11.1. ESTABLISHED COMPANIES
    11.1.1. ESTABLISHED COMPANIES AND SWOT
    11.2. EMERGING COMPANIES
    11.2.1. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS
    12 ABBREVIATIONS

    LIST OF TABLES
    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU
    TABLE 03: MAJOR ACQUISITIONS AND MERGERS IN LIVER DISEASES THERAPEUTIC AREA
    TABLE 04: MAJOR COLLABORATIVE AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA
    TABLE 05: MAJOR LICENSING AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA
    TABLE 06: MAJOR PARTNERSHIPS IN LIVER DISEASES THERAPEUTIC AREA
    TABLE 07: PHASE 3 MOLECULES IN THE LIVER DRUG PIPELINE
    TABLE 08: PHASE 2 MOLECULES IN THE LIVER DISEASES DRUG PIPELINE
    TABLE 09: PHASE 1 MOLECULES IN THE LIVER DRUG PIPELINE
    TABLE 10: PRECLINICAL MOLECULES IN THE LIVER DISEASE DRUG PIPELINE
    TABLE 11: EARLY R&D MOLECULES IN THE LIVER DISEASE DRUG PIPELINE
    TABLE 12: LIVER CIRRHOSIS PIPELINE MOLECULES, BY INDICATION TYPE
    TABLE 13: LIVER DISEASES DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 14: LIVER DISEASES DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
    TABLE 15: LIVER DISEASES DRUG PIPELINE MOLECULES BY INJECTABLE AS ROUTE OF ADMINISTRATION
    TABLE 16: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO FXR DRUG CLASS
    TABLE 17: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO TLR INHIBITORS DRUG CLASS
    TABLE 18: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 19: LIVER CIRRHOSIS PIPELINE DRUGS CLINICAL TRIALS SUMMARY
    TABLE 20: CENICRIVIROC (CVC) AURORA STUDY DESIGN
    TABLE 21: SELADELPAR ENHANCE STUDY DESIGN
    TABLE 22: ELAFIBRANOR RESOLVE-IT STUDY DESIGN
    TABLE 23: OCA REGENERATE STUDY DESIGN
    TABLE 24: OCA REVERSE STUDY DESIGN
    TABLE 25: ARAMCHOL ARREST STUDY DESIGN
    TABLE 26: MGL-3196 PHASE 2 STUDY DESIGN
    TABLE 27: GLOBAL LIVER CIRRHOSIS MARKET BY DRUG CLASS, MARKET SIZE (2017) AND FORECAST (2018-2028)
    TABLE 28: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 29: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 30: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 31: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 32: GLOBAL BETA-BLOCKERS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)
    TABLE 33: GLOBAL HORMONES MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)
    TABLE 34: GLOBAL ANTIBIOTICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 35: GLOBAL AMMONIA REDUCER MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 36: GLOBAL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 37: GLOBAL LIVER CIRRHOSIS MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 38: GLOBAL LIVER CIRRHOSIS MARKET FOR INJECTABLE DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 39: GLOBAL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 40: GLOBAL LIVER CIRRHOSIS MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 41: GLOBAL LIVER CIRRHOSIS MARKET FOR RETAIL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 42: GLOBAL LIVER CIRRHOSIS MARKET FOR ONLINE PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 43: GLOBAL LIVER CIRRHOSIS MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 44: US LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 45: US DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 46: US ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 47: US LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 48: US LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 49: UK LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 50: UK DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 51: UK ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 52: UK LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 53: UK LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 54: GERMANY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 55: GERMANY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 56: GERMANY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 57: GERMANY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 58: GERMANY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 59: FRANCE LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 60: FRANCE DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 61: FRANCE ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 62: FRANCE LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 63: FRANCE LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 64: ITALY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 65: ITALY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 66: ITALY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 67: ITALY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 68: ITALY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 69: SPAIN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 70: SPAIN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 71: SPAIN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 72: SPAIN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 73: SPAIN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 74: JAPAN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 75: JAPAN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 76: JAPAN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 77: JAPAN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 78: JAPAN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 79: CHINA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 80: CHINA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 81: CHINA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 82: CHINA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 83: CHINA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 84: INDIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 85: INDIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 86: INDIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 87: INDIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 88: INDIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 89: BRAZIL LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 90: BRAZIL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 91: BRAZIL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 92: BRAZIL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 93: BRAZIL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 94: RUSSIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 95: RUSSIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 96: RUSSIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 97: RUSSIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 98: RUSSIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 99: ROW LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 100: ROW DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 101: ROW ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 102: ROW LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 103: ROW LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 104: MAJOR PRODUCTS: MERCK
    TABLE 105: MERCK’S NEW MOLECULAR ENTITIES UNDER REVIEW
    TABLE 106: MERCK’S PHASE 3 DRUG CANDIDATES
    TABLE 107: MERCK’S PHASE 2 DRUG CANDIDATES
    TABLE 108: APPROVALS AND LAUNCHES BY MERCK
    TABLE 109: R&D ACTIVITIES OF MERCK
    TABLE 110: CONFERENCES/EVENTS ATTENDED BY MERCK
    TABLE 111: RECENT DEVELOPMENTS MADE BY MERCK
    TABLE 112: MAJOR PRODUCTS: GSK
    TABLE 113: GSK’S KEY PIPELINE DRUG CANDIDATES
    TABLE 114: APPROVALS AND LAUNCHES BY GSK
    TABLE 115: R&D ACTIVITIES OF GSK
    TABLE 116: CONFERENCES/EVENTS ATTENDED BY GSK
    TABLE 117: RECENT DEVELOPMENTS MADE BY GSK
    TABLE 118: EMERGING OPPORTUNITIES IN LIVER DISEASES THERAPEUTIC AREA
    TABLE 119: TERNS PHARMACEUTICALS PIPELINE MOLECULES
    TABLE 120: R&D MILESTONES ACHIEVED, TERNS PHARMACEUTICALS
    TABLE 121: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA
    TABLE 122: R&D ACTIVITIES OF CAN-FITE BIOPHARMA
    TABLE 123: PRESENTATIONS/CONFERENCES/EVENTS BY CAN-FITE BIOPHARMA
    TABLE 124: PUBLICATIONS OF CAN-FITE BIOPHARMA
    TABLE 125: PARTNERSHIPS BY CAN-FITE BIOPHARMA
    TABLE 126: RECENT DEVELOPMENTS OF CAN-FITE BIOPHARMA
    TABLE 127: PIPELINE PRODUCTS OF EA PHARMA
    TABLE 128: PATENTS OF EA PHARMA
    TABLE 129: R&D ACTIVITIES OF EA PHARMA
    TABLE 130: PRESENTATIONS AND PUBLICATIONS BY EA PHARMA
    TABLE 131: MILESTONES ACHIEVED BY EA PHARMA
    TABLE 132: RECENT DEVELOPMENTS OF EA PHARMA
    TABLE 133: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA
    TABLE 134: R&D ACTIVITIES OF BIOVIE
    TABLE 135: RECENT DEVELOPMENTS OF BIOVIE
    TABLE 136: RECENT ACTIVITIES OF CIRIUS THERAPEUTICS
    TABLE 137: PUBLICATIONS ON LIVER BY CIRIUS THERAPEUTICS
    TABLE 138: PIPELINE PRODUCTS OF GENFIT
    TABLE 139: U.S PATENTS OF GENFIT
    TABLE 140: R&D ACTIVITIES OF GENFIT
    TABLE 141: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY GENFIT
    TABLE 142: PUBLICATIONS OF GENFIT
    TABLE 143: PIPELINE PRODUCTS OF CYMABAY THERAPEUTICS
    TABLE 144: U.S PATENTS OF CYMABAY THERAPEUTICS
    TABLE 145: R&D ACTIVITIES OF CYMABAY THERAPEUTICS
    TABLE 146: ANTICIPATED MILESTONES OF CYMABAY THERAPEUTICS
    TABLE 147: RECENT DEVELOPMENTS BY CYMABAY THERAPEUTICS
    TABLE 148: PRESENTATIONS/CONFERENCES/EVENTS BY CYMABAY THERAPEUTICS
    TABLE 149: R&D ACTIVITIES OF GALMED PHARMACEUTICALS LTD
    TABLE 150: PRESENTATIONS/CONFERENCES/EVENTS OF GALMED PHARMACEUTICALS LTD
    TABLE 151: PUBLICATIONS BY GALMED PHARMACEUTICALS LTD
    TABLE 152: RECENT DEVELOPMENTS OF GALMED PHARMACEUTICALS LTD
    TABLE 153: PIPELINE PRODUCTS OF ENYO PHARMA SA
    TABLE 154: R&D ACTIVITIES OF ENYO PHARMA SA
    TABLE 155: PRESENTATIONS/CONFERENCES/EVENTS BY ENYO PHARMA SA
    TABLE 156: RECENT DEVELOPMENTS OF ENYO PHARMA SA
    TABLE 157: PIPELINE PRODUCTS OF POXEL SA
    TABLE 158: ANTICIPATED MILESTONES OF POXEL SA
    TABLE 159: R&D ACTIVITIES OF POXEL SA
    TABLE 160: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY POXEL SA
    TABLE 161: POSTER PRESENTATIONS BY POXEL SA
    TABLE 162: RECENT DEVELOPMENTS OF POXEL SA

    LIST OF FIGURES

    FIGURE 1: GLOBAL LIVER CIRRHOSIS MARKET 2017-2028: MARKET SNAPSHOT
    FIGURE 2: GLOBAL LIVER CIRRHOSIS MARKET BY GEOGRAPHY 2017 V/S 2028
    FIGURE 3: LIVER CIRRHOSIS MARKET BY ROA, 2017
    FIGURE 4: LIVER CIRRHOSIS MARKET BY DISTRIBUTION CHANNEL, 2017
    FIGURE 5: KEY PIPELINE EVENTS, 2020-2035
    FIGURE 6: CIRRHOSIS OF THE LIVER
    FIGURE 7: PATHOGENESIS AND PATHOPHYSIOLOGY OF CIRRHOSIS OF THE LIVER
    FIGURE 8: ETILOGY AND COMPLICATIONS OF CIRRHOSIS OF THE LIVER
    FIGURE 9: CLASSIFICATION OF CIRRHOSIS OF THE LIVER
    FIGURE 10: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU
    FIGURE 11: OVERALL DEALS ACTIVITY IN LIVER DISEASES THERAPEUTIC AREA
    FIGURE 12: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 13: DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 14: LIVER CIRRHOSIS PIPELINE SPLIT BY INDICATION TYPE
    FIGURE 15: DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 16: LIVER DISEASE DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 17: DRUG CLASS CLASSIFICATION OF LIVER DISEASES DRUG PIPELINE
    FIGURE 18: ONGOING CLINICAL TRIAL SUMMARY
    FIGURE 19: ANTIVIRAL DRUGS HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
    FIGURE 20: ORAL ROUTE OF ADMINISTRATION IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
    FIGURE 21: RETAIL PHARMACIES ARE EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
    FIGURE 22: US IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
    FIGURE 23: FINANCIAL INFORMATION OF MERCK, 2018
    FIGURE 24: SWOT ANALYSIS OF MERCK
    FIGURE 25: FINANCIAL INFORMATION, GSK
    FIGURE 26: SWOT ANALYSIS OF GSK

Pricing

Individual Pricing $3500

Corporate Pricing $3500

Enterprise Pricing $3500

(We are offering all the above license types for a single price!!)